140 related articles for article (PubMed ID: 17004270)
41. Design, synthesis, and structural studies on potent biaryl inhibitors of type II dehydroquinases.
Payne RJ; Riboldi-Tunnicliffe A; Kerbarh O; Abell AD; Lapthorn AJ; Abell C
ChemMedChem; 2007 Jul; 2(7):1010-3. PubMed ID: 17487901
[No Abstract] [Full Text] [Related]
42. Structure-based design of a potent and selective small peptide inhibitor of Mycobacterium tuberculosis 6-hydroxymethyl-7, 8-dihydropteroate synthase: a computer modelling approach.
Rao GS; Kumar M
Chem Biol Drug Des; 2008 Jun; 71(6):540-5. PubMed ID: 18482337
[TBL] [Abstract][Full Text] [Related]
43. Reducing the Flexibility of Type II Dehydroquinase for Inhibition: A Fragment-Based Approach and Molecular Dynamics Study.
Peón A; Robles A; Blanco B; Convertino M; Thompson P; Hawkins AR; Caflisch A; González-Bello C
ChemMedChem; 2017 Sep; 12(18):1512-1524. PubMed ID: 28791799
[TBL] [Abstract][Full Text] [Related]
44. [Bacterial type II topoisomerases as targets for antibacterial drugs].
Pietrusiński M; Staczek P
Postepy Biochem; 2006; 52(3):271-82. PubMed ID: 17201062
[TBL] [Abstract][Full Text] [Related]
45. Evidence that the active site in type II dehydroquinase from Streptomyces coelicolor is near the single tryptophan.
Boam DJ; Price NC; Kelly SM; Krell T; Coggins JR
Biochem Soc Trans; 1997 Feb; 25(1):348; replaces 93S. PubMed ID: 9147947
[No Abstract] [Full Text] [Related]
46. Irreversible covalent modification of type I dehydroquinase with a stable Schiff base.
Tizón L; Maneiro M; Peón A; Otero JM; Lence E; Poza S; van Raaij MJ; Thompson P; Hawkins AR; González-Bello C
Org Biomol Chem; 2015 Jan; 13(3):706-16. PubMed ID: 25370445
[TBL] [Abstract][Full Text] [Related]
47. A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.
Shen H; Wang F; Zhang Y; Huang Q; Xu S; Hu H; Yue J; Wang H
FEBS J; 2009 Jan; 276(1):144-54. PubMed ID: 19032598
[TBL] [Abstract][Full Text] [Related]
48. The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics.
Yuan Z; White RJ
Biochem Pharmacol; 2006 Mar; 71(7):1042-7. PubMed ID: 16289392
[TBL] [Abstract][Full Text] [Related]
49. Mechanistic insight into the reaction catalysed by bacterial type II dehydroquinases.
Coderch C; Lence E; Peón A; Lamb H; Hawkins AR; Gago F; González-Bello C
Biochem J; 2014 Mar; 458(3):547-57. PubMed ID: 24392963
[TBL] [Abstract][Full Text] [Related]
50. Crystal structures of Staphylococcus aureus type I dehydroquinase from enzyme turnover experiments.
Nichols CE; Lockyer M; Hawkins AR; Stammers DK
Proteins; 2004 Aug; 56(3):625-8. PubMed ID: 15229896
[No Abstract] [Full Text] [Related]
51. Carbonic anhydrase inhibitors: the X-ray crystal structure of the adduct of N-hydroxysulfamide with isozyme II explains why this new zinc binding function is effective in the design of potent inhibitors.
Temperini C; Winum JY; Montero JL; Scozzafava A; Supuran CT
Bioorg Med Chem Lett; 2007 May; 17(10):2795-801. PubMed ID: 17346964
[TBL] [Abstract][Full Text] [Related]
52. Microbial genomics and drug discovery: exploring innovative routes of drug discovery in the postgenomic era.
Dougherty TJ; Miller PF
IDrugs; 2006 Jun; 9(6):420-2. PubMed ID: 16752312
[TBL] [Abstract][Full Text] [Related]
53. Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
Wiener JJ; Gomez L; Venkatesan H; Santillán A; Allison BD; Schwarz KL; Shinde S; Tang L; Hack MD; Morrow BJ; Motley ST; Goldschmidt RM; Shaw KJ; Jones TK; Grice CA
Bioorg Med Chem Lett; 2007 May; 17(10):2718-22. PubMed ID: 17382544
[TBL] [Abstract][Full Text] [Related]
54. 4-Oxalocrotonate tautomerase, its homologue YwhB, and active vinylpyruvate hydratase: synthesis and evaluation of 2-fluoro substrate analogues.
Johnson WH; Wang SC; Stanley TM; Czerwinski RM; Almrud JJ; Poelarends GJ; Murzin AG; Whitman CP
Biochemistry; 2004 Aug; 43(32):10490-501. PubMed ID: 15301547
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and biochemical evaluation of selective inhibitors of class II fructose bisphosphate aldolases: towards new synthetic antibiotics.
Fonvielle M; Coinçon M; Daher R; Desbenoit N; Kosieradzka K; Barilone N; Gicquel B; Sygusch J; Jackson M; Therisod M
Chemistry; 2008; 14(28):8521-9. PubMed ID: 18688832
[TBL] [Abstract][Full Text] [Related]
56. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and characterization of cytidine derivatives that inhibit the kinase IspE of the non-mevalonate pathway for isoprenoid biosynthesis.
Crane CM; Hirsch AK; Alphey MS; Sgraja T; Lauw S; Illarionova V; Rohdich F; Eisenreich W; Hunter WN; Bacher A; Diederich F
ChemMedChem; 2008 Jan; 3(1):91-101. PubMed ID: 18033714
[TBL] [Abstract][Full Text] [Related]
58. Structural and functional characterization of Staphylococcus aureus dihydrodipicolinate synthase.
Girish TS; Sharma E; Gopal B
FEBS Lett; 2008 Aug; 582(19):2923-30. PubMed ID: 18671976
[TBL] [Abstract][Full Text] [Related]
59. Crystal structure and kinetic study of dihydrodipicolinate synthase from Mycobacterium tuberculosis.
Kefala G; Evans GL; Griffin MD; Devenish SR; Pearce FG; Perugini MA; Gerrard JA; Weiss MS; Dobson RC
Biochem J; 2008 Apr; 411(2):351-60. PubMed ID: 18062777
[TBL] [Abstract][Full Text] [Related]
60. Synthesis of 3-alkyl enol mimics inhibitors of type II dehydroquinase: factors influencing their inhibition potency.
Blanco B; Sedes A; Peón A; Lamb H; Hawkins AR; Castedo L; González-Bello C
Org Biomol Chem; 2012 May; 10(18):3662-76. PubMed ID: 22447158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
